Physician profile
Edward C Wade
NPI 1366445645
$10,244.01
in general payments reported to CMS, 2019-2025
34 companies · $912 in 2025
The $912 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,070 · 2020: $1,005 · 2021: $1,904 · 2022: $1,440 · 2023: $1,679 · 2024: $1,233 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,899.30 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Abbvie INC. | $1,069.36 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $599.86 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $510.34 | 2019-2023 | |
| Glaukos Corporation | $417.31 | 2021-2025 | Idose, Idosetr, Ce-Marked Kxla System |
| Eyevance Pharmaceuticals LLC | $393.36 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $378.22 | 2022-2025 | Miebo, Xiidra, Ic-8 Apthera Iol |
| Sun Pharmaceutical Industries INC. | $321.25 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $267.10 | 2019-2021 | |
| Oyster Point Pharma, INC. | $230.98 | 2022-2024 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $217.65 | 2019-2024 | |
| Astellas Pharma US INC | $209.76 | 2023-2025 | Izervay |
| Harrow Eye, LLC | $201.70 | 2023-2025 | Iheezo, Vevye |
| Shire North American Group INC | $172.95 | 2019 | |
| New World Medical,INC. | $171.81 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $159.35 | 2022-2024 | Omni Surgical System, Tearcare System |
| Rxsight INC | $155.79 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Kala Pharmaceuticals, INC. | $118.28 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.61 | 2019-2021 | |
| Ocular Therapeutix, INC. | $99.58 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $95.20 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $81.72 | 2020-2023 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $73.90 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $46.55 | 2023 | Iolmaster 700 |
| Optos, INC. | $44.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.60 | 2020 | |
| Ani Pharmaceuticals, INC. | $30.48 | 2023 | Purified Cortrophin Gel |
| Biogen, INC. | $29.20 | 2023 | |
| Amgen INC. | $25.00 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $24.20 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $16.46 | 2023 | Tepezza |
| Omeros Corporation | $14.51 | 2020 | |
| Staar Surgical Company | $14.36 | 2019 | |
| Lumenis, INC | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.